Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico

Overview of attention for article published in npj Vaccines, May 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#25 of 838)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (95th percentile)

So far, Altmetric has seen 381 X posts from 354 X users, with an upper bound of 1,692,186 followers.

RT @soylajefita: Este es el único artículo que encontré publicado, sobre la Fase 1 https://t.co/7p60YiI7Fb

RT @soylajefita: Este es el único artículo que encontré publicado, sobre la Fase 1 https://t.co/7p60YiI7Fb

RT @soylajefita: Este es el único artículo que encontré publicado, sobre la Fase 1 https://t.co/7p60YiI7Fb

RT @soylajefita: Este es el único artículo que encontré publicado, sobre la Fase 1 https://t.co/7p60YiI7Fb

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 377 additional X posts.